Consistently, our data suggest that ACSL1 gene expression is upregulated by G0S2 ectopic expression in CML (Figure S8A), and therefore may play a role in its tumour suppressor activity during CML disease progression and TKI response. The gene discussed is ACSL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.